Management tracks: Seattle Genetics, SurModics

Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) said CMO Jonathan Drachman has stepped down. He is succeeded by Roger Dansey, who was therapeutic area head for late-stage oncology at Merck & Co. Inc. (NYSE:MRK).

Medical device and diagnostics company SurModics Inc. (NASDAQ:SRDX) said CFO Andrew LaFrence will resign, effective May 25. He will be succeeded by VP of Corporate Development and Strategy Timothy Arens as interim CFO. LaFrence will join immuno-oncology company Biothera Pharmaceuticals Inc. (Eagan, Minn.) as SVP and CFO, effective May 29...